HACKENSACK, N.J., April 4, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the presentation of data from applications of Champions TumorGrafts® in clinical and research settings in multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2014.
The presentations will be delivered during the general poster session in Halls A-E of the San Diego Convention Center from 8 a.m. to noon PDT on Monday, April 7.
Title: The Champions TumorGraft® Bank: A demographically-rich repository of preclinical TumorGraft models
Presented By: Tin Khor, Ph.D., Champions Oncology
Location: Section 8, Poster Board 6
Abstract Number: 1187
Title: Multifactorial biological processes govern engraftment of patient-derived tumor tissue in immunodeficient mice
Presented By: David Vasquez-Dunddel, M.D., Ph.D., Champions Oncology
Location: Section 8, Poster Board 9
Abstract Number: 1190
Title: Humanized mouse models for personalized preclinical testing of monoclonal antibodies targeting immune checkpoints
Presented By: Gilson Baia, Ph.D., Champions Oncology
Location: Section 28, Poster Board 28
Abstract Number: 1674
Title: Development of a spontaneous in vivo cachexia model using the Champions TumorGraft® platform
Presented By: Nathan Anderson, Champions Oncology
Location: Section 9, Poster Board 14
Abstract Number: 1217
Title: Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models
Presented By: Timothy Heuer, Ph.D., 3-V Biosciences
Location: Section 33, Poster Board 28
Abstract Number: 1815
About Champions TumorGrafts®
Champions TumorGraft® is a personalized approach used to guide physician treatment decisions for cancer patients. A piece of the patient's living tumor is removed during surgery or biopsy and implanted in immune-deficient mice. After the TumorGraft grows, still closely resembling the patient's tumor, Champions Oncology tests drug treatments in the TumorGraft and measures the response. Champions' TumorGraft experience has demonstrated high rates of predictability using multiple therapies, including single-agent and combination chemotherapy regimens, targeted biological drugs and anti-angiogenics.
Every TumorGraft is preserved as a living sample for future patient use. These banked TumorGrafts can be re-grown and tested in the event of cancer progression or recurrence. They have been successfully utilized in most solid tumor types including colorectal, ovarian, lung, breast, sarcoma, pancreatic, stomach, esophageal and others.
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice to create TumorGrafts that preserve the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. For more information, please visit www.championsoncology.com.
SOURCE Champions Oncology